Genelux (NASDAQ:GNLX) Trading Up 4.1%
Genelux (NASDAQ:GNLX) Trading Up 4.1%
Genelux Co. (NASDAQ:GNLX – Get Rating) shares were up 4.1% during mid-day trading on Thursday . The company traded as high as $31.70 and last traded at $29.25. Approximately 8,146 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 147,528 shares. The stock had previously closed at $28.11.
Analyst Upgrades and Downgrades
Separately, Benchmark started coverage on shares of Genelux in a report on Wednesday, February 15th. They issued a "speculative buy" rating and a $10.00 price objective on the stock.
Genelux Stock Down 5.3 %
Genelux Company Profile
(Get Rating)
Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus.
Featured Articles
- Get a free copy of the StockNews.com research report on Genelux (GNLX)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ's Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
Genelux Co. (NASDAQ:GNLX – Get Rating) shares were up 4.1% during mid-day trading on Thursday . The company traded as high as $31.70 and last traded at $29.25. Approximately 8,146 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 147,528 shares. The stock had previously closed at $28.11.
吉勒聯盟股份有限公司（納斯達克：GNLX-獲得評級）週四中午交易期間，股票上漲了 4.1％。該公司的交易價格高達 31.70 美元，最後交易價為 29.25 美元。在日間交易期間，約 8,146 股股份轉手，較每日平均成交量 147,528 股下跌 94％。該股票之前已收盤 28.11 美元。
Analyst Upgrades and Downgrades
分析師升級和降級
Separately, Benchmark started coverage on shares of Genelux in a report on Wednesday, February 15th. They issued a "speculative buy" rating and a $10.00 price objective on the stock.
另外，基準在 2 月 15 日（週三）的一份報告中開始對基納盧公司的股票覆蓋。他們對股票發出了「投機性買入」評級和 10.00 美元的價格目標。
Genelux Stock Down 5.3 %
基因盧股票下降 5.3%
Genelux Company Profile
日內盧公司簡介
(Get Rating)
(取得評分)
Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus.
格內盧公司是一家臨床階段的生物製藥公司。它專注於為患有侵略性和/或難以治療的實體腫瘤類型的患者開發下一代單體免疫療法的管道。該公司最先進的候選產品 Olvi-VEC 是一種專有的，改性的疫苗病毒菌株，一種穩定的 DNA 病毒。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Genelux (GNLX)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ's Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
- 獲取有關基因盧經濟聯盟（GNLX）的研究報告的免費副本
- 化石集團：您應該在 2023 年押注自由消費嗎？
- BJ 批發俱樂部股票在強勁業績後走高
- 每月房地產收入即將變得更大
- 3 千禧一代投資者的大型股息挑戰者
- Sea 有限公司處於 100％ 拉力賽的邊緣，您應該購買嗎？
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
接收基納盧日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Genelux 及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧